Untitled

HealthTrust presents…“Who’s the Real Alfa? Andexanet Alfa versus 4F-PCC for Direct Oral Anticoagulants (DOAC) Reversal”

Before approval of andexanet alfa (Andexxa), off-label treatment with 4-factor prothrombin complex concentrate (4F-PCC) was the unquestioned first line therapy for the management of life-threatening hemorrhages related to the use of direct oral anticoagulants (DOAC). The approval of Andexxa sparked an ongoing debate among clinicians regarding which agent should be used for reversal of life-threatening hemorrhages associated with oral factor Xa inhibitors. Even the agents considered the safest such as rivaroxaban and apixaban come with significant risk. These agents are associated with intracranial bleeding rates of up to 4% and in-hospital mortality rates of up to 40%. As the use of these DOACs becomes more prevalent, there needs to be a clear and concise recommendation regarding reversal of these agents. Current literature will be presented around which option is the safest and most effective for reversal of hemorrhage related to these products, so that attendees can make an informed decision on which option is the safest and most effective for reverasal of hemorrhage related to these products.

Learning Objectives for Pharmacists & Nurses  |  At the end of this session, participants should be able to:

1. Recall the mechanisms of action of four-factor prothrombin complex concentrate (4F-PCC) and andexanet alfa
2. Identify the outcomes of studies utilizing 4F-PCC and andexanet alfa for direct oral anticoagulant (DOAC) reversal
3. Describe the pros and cons of 4F-PCC and andexanet alfa use in DOAC reversal

Presenter:

Harrison Hyman, PharmD  |  PGY-1 Resident  |  McLeod Health

Target Audience: Pharmacists, Nurses &  Physicians

CE Credit: Approved for Nurses, pending for Pharmacists

This program is pending approval for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this activity is pending. The activity is approved for Nurses & pending for Pharmacists for 1 hour (.1 CEUs) of continuing education credit for those who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN, provider approved by the California Board of Registered Nursing, Provider Number CEP13019, for 1 contact hour. 1.0 contact hours approved for Nurses.

Note about CE credit: If you plan to obtain credit for a live session, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.